Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers

OBJECTIVES: Data suggest that some licensed antiretroviral doses could be reduced. We assessed the safety, tolerability and pharmacokinetics of lopinavir/ritonavir at doses of 400/100, 200/150 and 200/50 mg twice daily in HIV-negative volunteers (http://clinicaltrials.gov/ct2/show/NCT00985543). METH...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Jackson, Akil, Hill, Andrew, Puls, Rebekah, Else, Laura, Amin, Janaki, Back, David, Lin, Enmoore, Khoo, Saye, Emery, Sean, Morley, Roland, Gazzard, Brian, Boffito, Marta
Médium: Artigo
Jazyk:Inglês
Vydáno: 2010
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3594886/
https://ncbi.nlm.nih.gov/pubmed/21172791
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkq468
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky